Shares of the gene-editing titan CRISPR Therapeutics (NASDAQ: CRSP) are seemingly in for a bad day. The biotech's stock dropped by nearly 10% in premarket trading today in response to an early look at phase 1 trial results for its blood cancer candidate CTX110.
Are CRISPR stocks a good investment?
Oct 08, 2021 · Oct 8, 2021 2:35PM EDT. YouTube. Shares of leading gene editing company CRISPR Therapeutics CRSP are sliding on Friday, down about 4.8% in midday trading Friday and on its way to a losing week ...
How to invest in CRISPR?
Jul 24, 2018 · What happened. Shares of the three leading companies developing human therapeutics based on CRISPR gene-editing technology fell as much as 11.4% today. There was no new news that could be ...
What is CRSP stock?
Oct 07, 2021 · The stock is down roughly 8.9% in the month so far. CRSP data by YCharts CRISPR Therapeutics is valued at roughly $7.8 billion and trades …
How do you use CRISPR?
Oct 13, 2021 · Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
Is CRISPR stock a buy?
Will CRISPR Therapeutics stock go up?
The 21 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 145.00, with a high estimate of 220.00 and a low estimate of 64.00. The median estimate represents a +201.83% increase from the last price of 48.04.
Is CRSP a good buy?
Whats going on with CRISPR?
What will CRSP stock be worth in 2025?
Is CRISPR a buy Zacks?
...
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.97% |
| 2 | Buy | 18.45% |
| 3 | Hold | 10.03% |
| 4 | Sell | 5.70% |
Is CRISPR stock overvalued?
Is NIO a buy Zacks?
Who owns CRSP stock?
| Stockholder | Stake | Shares owned |
|---|---|---|
| Ecor1 Capital LLC | 1.40% | 1,077,483 |
| Bellevue Asset Management AG | 1.26% | 974,684 |
| BlackRock Fund Advisors | 1.21% | 930,081 |
| Armistice Capital LLC | 1.16% | 892,000 |
What is the most notorious news about CRISPR that has happened in 2020?
Can CRISPR go wrong?
Is CRISPR the future of medicine?
What happened
Shares of the three leading companies developing human therapeutics based on CRISPR gene-editing technology fell as much as 11.4% today. There was no new news that could be interpreted as detrimental to CRISPR Therapeutics (NASDAQ: CRSP), Editas Medicine (NASDAQ: EDIT), or Intellia Therapeutics (NASDAQ: NTLA).
So what
On July 16, scientists published a study in Nature Biotechnology demonstrating that using CRISPR tools to edit faulty DNA sequences can lead to unintended deletions and rearrangements of genetic material. The lead author, Dr. Allan Bradley, issued a cautious summary of the study:
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
Vertex Pharmaceuticals (NASDAQ: VRTX) has worked closely with CRISPR Therapeutics (NASDAQ: CRSP) for quite a while to develop a CRISPR gene-editing therapy targeting rare blood diseases. Recently, Vertex expanded a partnership focused on CRISPR gene editing, but it's not with CRISPR Therapeutics. In this Motley Fool Live video recorded on Aug.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.07, marking a +0.56% move from the previous day.
Could CRISPR Therapeutics Stock Help You Retire a Millionaire?
The pandemic has brought a new awareness to genetic medicine and scientific research as a whole. One of the pioneers of the technology is CRISPR Therapeutics (NASDAQ: CRSP). It's making its own news and positioned to be one of the leading companies in this new era of gene-based medicine.
12 Best ARK Stocks To Invest In
In this article, we discuss the 12 best ARK stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best ARK Stocks to Invest In. As technology and growth stocks surged during the pandemic, ARK Investment Management and Cathie Wood became two of retail investors’ favorites over the previous […]
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights
Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.
Earnings Growth & Price Strength Make CRISPR Therapeutics AG (CRSP) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
How Are Genomics ETFs Responding to Q2 Earnings?
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
The gene-editing pioneer announced the pricing of a public stock offering
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) are falling today, down by 9.7% as of 1:53 p.m. EST, after the company announced the pricing of a public stock offering. The gene-editing pioneer said it will offer up to 4.89 million shares at $64.50 apiece, which would generate gross proceeds of up to $315 million.
So what
CRISPR Therapeutics is exploring many applications for its gene-editing technology. For instance, CTX001 attempts to engineer cells in bone marrow such that the resulting red blood cells generated can function properly and relieve individuals suffering from sickle cell disease or beta thalassemia.
Now what
Even after taking today's tumble into account, shares of CRISPR Therapeutics are up 112% since the beginning of the year. Given a pipeline that is (or soon will be) buzzing with activity, it makes sense for the pharma stock to bolster its cash position.
Is CRISPR Therapeutics a buy right now?
17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock.
What stocks does MarketBeat like better than CRISPR Therapeutics?
Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CRISPR Therapeutics wasn't one of them.
Are investors shorting CRISPR Therapeutics?
CRISPR Therapeutics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 2,940,000 shares, an increase of 14.0% from the July 29th total of 2,580,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is currently 2.3 days.
When is CRISPR Therapeutics' next earnings date?
CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.#N#View our earnings forecast for CRISPR Therapeutics.
How were CRISPR Therapeutics' earnings last quarter?
CRISPR Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings data on Thursday, July, 29th. The company reported $9.44 EPS for the quarter, topping analysts' consensus estimates of $3.52 by $5.92. The firm earned $900.70 million during the quarter, compared to analyst estimates of $678.05 million.
How has CRISPR Therapeutics' stock been impacted by COVID-19?
CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has increased by 179.0% and is now trading at $120.74.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for CRSP?
17 Wall Street analysts have issued 1-year price targets for CRISPR Therapeutics' stock. Their forecasts range from $110.00 to $210.00. On average, they expect CRISPR Therapeutics' share price to reach $160.69 in the next year.
CRISPR Therapeutics Media Sentiment
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Media Coverage
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
CRISPR Therapeutics (NASDAQ CRSP) News Headlines Today
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
